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Abstract
Background: Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity
against many common pathogens associated with community-acquired pneumonia (CAP), as well
as penetration into lung tissues that suggests effectiveness in hospitalized CAP patients. The aim of
the present study was to compare the efficacy and safety of intravenous (IV) tigecycline with IV
levofloxacin in hospitalized adults with CAP.
Methods: In this prospective, double-blind, non-inferiority phase 3 trial, eligible patients with a
clinical diagnosis of CAP supported by radiographic evidence were stratified by Fine Pneumonia
Severity Index and randomized to tigecycline or levofloxacin for 7-14 days of therapy. Co-primary
efficacy endpoints were clinical response in the clinically evaluable (CE) and clinical modified intent-
to-treat (c-mITT) populations at test-of-cure (Day 10-21 post-therapy).
Results: Of the 428 patients who received at least one dose of study drug, 79% had CAP of mild-
moderate severity according to their Fine score. Clinical cure rates for the CE population were
88.9% for tigecycline and 85.3% for levofloxacin. Corresponding c-mITT population rates were
83.7% and 81.5%, respectively. Eradication rates for Streptococcus pneumoniae were 92% for
tigecycline and 89% for levofloxacin. Nausea, vomiting, and diarrhoea were the most frequently
reported adverse events. Rates of premature discontinuation of study drug or study withdrawal
because of any adverse event were similar for both study drugs.
Conclusion: These findings suggest that IV tigecycline is non-inferior to IV levofloxacin and is
generally well-tolerated in the treatment of hospitalized adults with CAP.
Trial registration: NCT00081575
Published: 9 September 2009
BMC Pulmonary Medicine 2009, 9:44 doi:10.1186/1471-2466-9-44
Received: 6 January 2009
Accepted: 9 September 2009
This article is available from: http://www.biomedcentral.com/1471-2466/9/44
© 2009 Tanaseanu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
Page 2 of 11
(page number not for citation purposes)
Background
Community-acquired pneumonia (CAP) occurs in
approximately one to five per 1000 of the adult popula-
tion per year [1-3] and is associated with rates of mortality
ranging from a low of 5% up to 30%-50% for patients
with multiple comorbidities and requiring intensive care
[2,4,5]. Streptococcus pneumoniae (the most common etio-
logic agent), nontypeable Haemophilus influenzae, and the
atypical organisms (i.e., Mycoplasma pneumoniae, Chlamy-
dia pneumoniae, and Legionella pneumophila) are the most
frequently isolated pathogens from patients of any age
who require hospitalization for CAP [2,5-10]. Rates of
multidrug-resistant S. pneumoniae have been reported to
be >30% worldwide and H. influenzae beta-lactamase pro-
duction varies by country, ranging from 12% to 27% [11-
14].
Initial antimicrobial treatment for patients with CAP
should provide appropriate coverage against the most
common causative organisms, including resistant strains,
while evaluating whether monotherapy or combination
therapy is required. For hospitalized patients who do not
require admission to the intensive care unit (ICU), the
most recent guidelines published by several authorities
recommend the combination of an extended-spectrum
cephalosporin or beta-lactam/beta-lactamase inhibitor
combination with the option of adding a macrolide or
monotherapy with a newer fluoroquinolone [5,7-10].
Tigecycline, a first-in-class, expanded broad-spectrum gly-
cylcycline, demonstrates in vitro activity against many
commonly encountered respiratory bacteria, including
multiple resistant gram-positive, gram-negative, anaero-
bic, and "atypical" bacteria such as multidrug-resistant S.
pneumoniae and beta-lactamase producing H. influenzae
[15]. In this first phase 3 study in CAP with tigecycline, the
primary objective was to compare the efficacy and safety
of intravenous (IV) tigecycline with IV levofloxacin in the
treatment of patients with CAP requiring hospitalization.
Levofloxacin was chosen as the comparator because it is
commonly prescribed worldwide and it is recommended
in guidelines for the treatment of CAP [5,8-10].
Methods
Study design and patient enrolment criteria
A prospective, double-blind (third-party unblinded), ran-
domized, multicentre, phase 3 study was conducted from
January 2004 to January 2005 at 62 centres in 20 countries
in Europe, Africa, and the Asia Pacific region. Approxi-
mately 400 subjects were enrolled to obtain 240 clinically
evaluable subjects and to ensure with 90% probability
that the lower bound of a two-sided 95% confidence
interval for the true difference in efficacy would not be less
than -15%. The protocol was reviewed and approved by
each investigator's independent ethics committee or insti-
tutional review board in accordance with local regulations
and good clinical practices. Written informed consent was
to be obtained from each patient or his or her guardian
before commencement of any study-specific procedure.
Subjects were stratified at randomization by the Fine
Pneumonia Severity Index score (V, IV, III, or less than III)
[16]. In a post-hoc analysis, the severity of each subject's
pneumonia was also categorized using an estimate of the
CURB-65 prediction severity tool, using a notation of
"altered mental status" under medical history for "confu-
sion" [17]. Subjects were assigned in a 1:1 ratio to treat-
ment using a computerized system of automated
telephone randomization, to receive either IV tigecycline
(initial 100-mg dose given by infusion over a 60-minute
period, followed by 50 mg IV every 12 hours) or levo-
floxacin (500 mg once-daily or twice-daily based on inves-
tigator's discretion, administered over a 60-minute
period; or for subjects with creatinine clearance 20-49 mL/
min, an initial 500-mg dose followed by 250 mg once- or
twice-daily) for at least 7 days, unless a clinical failure, and
up to a maximum of 14 days. An unblinded third party
prepared the masked test articles and an unblinded nurse
administered the test article. The person(s) responsible for
preparing and/or administering the test article were not
involved in the assessment or evaluation of the subject for
safety or efficacy. Each subject's blinded data set was
reviewed to ensure the accuracy and integrity of the data.
Patient population
Male or non-pregnant/non-lactating female patients ≥18
years of age (in Bulgaria only from 18 to ≤ 70 years of age
due to local requirement) hospitalized with clinical signs
and symptoms of CAP who required initial parenteral
therapy for at least 7 days were considered for enrolment.
Each patient was to have fever within 24 hours of rand-
omization (oral temperature >38°C/100.4°F, axillary
temperature >38.1°C/100.6°F, tympanic membrane tem-
perature >38.5°C/101.2°F, or a rectal/core temperature ≥
39°C/102.2°F) or hypothermia (core temperature
<35°C/95°F). Each patient also was to have at least two of
the following signs and symptoms consistent with CAP:
cough with production of purulent or mucopurulent spu-
tum; auscultatory findings on pulmonary examination
suggestive of pulmonary consolidation (dullness to per-
cussion, rales/rhonchi, or bronchial breath sounds); dys-
pnoea or tachypnoea; white blood cell (WBC) count
>10,000/mm3, or >15% immature neutrophils (bands),
and/or leucopoenia with a total WBC count <4500/mm3;
and hypoxemia (PO2 < 60 mm Hg or oxygen saturation
<90% while the subject was breathing room air). Radio-
logically-confirmed evidence of a new or progressive infil-
trate(s) consistent with bacterial pneumonia within 48
hours before receiving the first dose of study drug was also
mandatory.BMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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Key exclusion criteria included: hospitalization within 14
days before the onset of symptoms; residence in a long-
term care facility ≥14 days before the onset of symptoms;
sustained shock or required treatment in an intensive care
unit; known or suspected concomitant bacterial infection
requiring treatment with an additional systemic antibacte-
rial agent; received more than one dose of systemic anti-
bacterial therapy (or received a once-daily antibiotic) to
treat this episode of CAP prior to receiving the first dose of
study drug, unless a clinical failure; and known or sus-
pected Pseudomonas, Pneumocystis carinii, Legionella pneu-
monia, or tuberculosis infection.
Clinical evaluations
Eligible patients were evaluated, and clinical signs and
symptoms recorded at serial visits: baseline (within 24
hours of first study drug dose), during treatment, early fol-
low-up (Day 2-4 post-therapy), and test-of-cure (Day 10-
21 post-therapy). Pulse oximetry and/or arterial blood
gases were obtained at baseline, end of therapy, early fol-
low-up, and at the test-of-cure visits. Chest x-rays were
obtained at baseline (within 48 hours of receiving first
dose of study drug) and were repeated at the test-of-cure
visit. Clinical responses were graded as cure, failure, or
indeterminate at the test-of-cure assessment.
Microbiologic evaluations
Sputum samples, when available, were collected prior to
initiation of study drug therapy and submitted to a local
laboratory for Gram staining, culture, and susceptibility
testing. Specimens obtained by deep expectoration or
nasotracheal aspiration were considered appropriate for
culture if the Gram stain revealed <10 squamous epithe-
lial cells and >25 leukocytes/low-power field. Blood spec-
imens (2 sets at least 15 minutes apart from 2 different
sites) were to be drawn for culture at enrolment, and if
positive were to be repeated at day 3 and at the discretion
of the investigator until confirmed negative, or if the sub-
ject was a treatment failure. Urine specimens were col-
lected at baseline for Legionella and pneumococcal urinary
antigens. Serology for Chlamydia,  Mycoplasma, and
Legionella was to be obtained for all patients at baseline
and 6 ± 2 weeks after the baseline collection of blood sam-
ples.
All aerobic and anaerobic bacterial isolates, regardless of
the source of cultured material, were to be identified and
tested at the investigator's laboratory and then confirmed
at a central laboratory (Covance Central Laboratory Serv-
ices, Inc., Geneva, Switzerland) according to standard pro-
cedures.
Safety and tolerability assessments
Each patient who received at least one dose of study drug
was evaluated for safety (modified intent-to-treat [mITT]
population) based on medical history and physical exam-
inations, reports of clinical adverse events (AEs), and find-
ings from 12-lead electrocardiograms (ECGs) and serum
chemistry, haematology, and coagulation tests. Adverse
events were to be recorded throughout the study period,
up to and including the test-of-cure visit (or 14 days after
the last dose of study drug, whichever was greater). Before
unblinding, the investigator categorized the severity of
each adverse event and the potential for relationship to
the study drug. Severity of nausea and vomiting was cate-
gorized according to the National Cancer Institute Com-
mon Toxicity Criteria: grade 1 (mild), 2 (moderate), 3
(severe), and 4 (life-threatening). Serious adverse events
(i.e., those that were life-threatening, led to prolongation
of the existing hospitalization, or caused persistent or sig-
nificant disability or incapacity, or death) were also
recorded.
Statistical analysis
The primary efficacy endpoint of the study was the clinical
response at the test-of-cure visit (10-21 days after therapy)
for the co-primary clinically evaluable (CE) and clinical
modified ITT (c-mITT) populations. Secondary analyses
included clinical response rates in the microbiologically
evaluable (ME) and microbiologic modified ITT (m-
mITT) populations, monomicrobial versus polymicrobial
infections, and by isolate, as well as microbiologic
response at the test-of-cure visit by patient and isolate.
Statistical analysis was performed by the Clinical Biosta-
tistics Department of Wyeth Research, Collegeville, PA.
Categorical baseline demographic and medical variables
were analyzed using the Fisher exact test. Continuous var-
iables were compared using a one-way analysis of variance
(ANOVA) model with treatment as a factor. Between-
group comparisons of adverse events were analyzed by
using the Fisher exact test. For laboratory tests, vital signs,
and ECG results, within-group changes from baseline
were analyzed by using a paired t-test and between-group
comparisons were made by using the analysis of covari-
ance, adjusting for baseline value. The difference between
treatment groups in the percentage of premature discon-
tinuation from study drug was evaluated by using a two-
sided Fisher exact test.
Non-inferiority of tigecycline compared with levofloxacin
was evaluated for clinical response by using a two-sided
95% confidence interval for the true difference in efficacy
(tigecycline minus levofloxacin) adjusted for the stratifi-
cation variable (Fine Pneumonia Severity Index score)
used at the time of randomization. Non-inferiority was
concluded if the lower limit of the two-sided 95% CI was
greater than or equal to -15%. For all subpopulation anal-
yses (e.g., monomicrobial versus polymicrobial infec-
tion), an adjusted difference between treatment groupsBMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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with its 95% CI was calculated from a generalized linear
model with a binomial probability function and an iden-
tity link (Proc GENMOD).
Results
A total of 449 patients were screened for study participa-
tion, of which 434 were randomly assigned to receive tige-
cycline or levofloxacin, constituting the intent-to-treat
(ITT) population, and 428 received at least 1 dose of study
medication, constituting the modified ITT (mITT) popu-
lation (Figure 1).
Demographics and baseline medical characteristics
Demographic and baseline medical characteristics for the
mITT population are summarized in Table 1 and were
similar for the two treatment groups, with a mean age of
49.8 ± 17.7 years and a slight predominance of male
enrolment (62%). All subjects required hospitalization
although most subjects were considered to have mild-
moderate CAP (79% with Fine score I-III). Demographic
and baseline medical characteristics in the CE population
displayed similar results (Table 1).
Clinical efficacy
The clinical efficacy of tigecycline was found to be non-
inferior (P < 0.001) to that of levofloxacin in the CE pop-
ulation, with clinical cure rates of 88.9% for tigecycline
versus 85.3% for levofloxacin (adjusted difference of 3.6,
95% CI -4.5, 11.8; P = 0.4025; Table 2). Analysis of clini-
cal response at the test-of-cure assessment for the CE pop-
ulation by Fine score category also showed the non-
inferiority of tigecycline compared with levofloxacin. Sim-
ilar findings were observed for clinical response using esti-
mated CURB-65 score distributions (Table 2). Clinical
cure rates for patients with diabetes were 100% (17/17)
for tigecycline- vs. 75% (12/16) for levofloxacin-treated
patients. Similar cure rates were reported for subjects with
impaired renal function (i.e., creatinine clearance ≤70
mL/min): 91.3% (42/46) for tigecycline and 78.3% (36/
46) for levofloxacin. Noninferiority of tigecycline was also
demonstrated in the c-mITT population (P < 0.001), with
clinical cure rates of 83.7% for tigecycline versus 81.5%
for levofloxacin (adjusted difference of 2.0, 95% CI -5.5,
9.6; P < 0.6269). For both the ME and m-mITT popula-
tions, tigecycline was also efficacious and statistically non-
inferior to levofloxacin. When analyzed by the type of
infection (polymicrobial and monomicrobial) for the ME
and m-mITT populations, the results were generally simi-
lar within each of the treatment groups, and no significant
differences in cure rates were observed between the two
treatment groups (Table 3).
In the tigecycline treatment group, the clinical cure rate for
patients with bacteremia (ME population, 83.3%; 10/12)
was similar to those who did not have bacteremia (91.9%;
68/74) at baseline. Corresponding rates for the levo-
floxacin group were 60% (3/5) and 91.3% (73/80),
respectively. Most of the cases of bacteremia were caused
by S. pneumoniae. In the tigecycline treatment group, the
cure rate for subjects with S. pneumoniae bacteremia (ME
population) was 90.9% (10/11), which was similar to
those who did not have bacteremia (90.7%; 68/75). Cor-
responding rates for the levofloxacin group were 60% (3/
5) and 91.3% (73/80), respectively.
Microbiologic efficacy
Eradication rates (generally presumed, based on clinical
response) at the test-of-cure visit for common respiratory
pathogens (defined by respiratory culture, urinary anti-
gen, or serology) within the ME population were similar
between the two treatment groups (Table 4). For S. pneu-
moniae, the most common isolate, eradication rates were
similar for tigecycline (92%) and levofloxacin (89%).
Both study drugs eradicated 100% of penicillin-interme-
diate (n = 8) and penicillin-resistant (n = 5) strains. M.
pneumoniae, the most commonly identified atypical
organism, was eradicated in 96% (24/25) of tigecycline-
and 92% (22/24) of levofloxacin-treated patients. There
were no obvious differences in the eradication rates of
other organisms, albeit the number of isolates was gener-
ally small.
Susceptibility data
Pretherapy  in vitro activity against baseline isolates for
tigecycline and levofloxacin for the ME population are
outlined in Table 5. The MIC90 for tigecycline against the
common respiratory pathogens was ≤1.0 μg/mL. Specifi-
cally, the mean MIC90 for tigecycline against S. pneumoniae
(all isolates) was 0.06 μg/mL. No patients were identified
with decreased susceptibility to tigecycline.
Safety and tolerability
Regardless of study drug causality or severity, the fre-
quency and distribution of treatment-emergent adverse
events (TEAEs) occurring in at least 3% of patients in
either treatment group is outlined in Table 6. Significantly
more tigecycline-treated patients (135; 62.5%) reported
one or more TEAEs compared with levofloxacin (100;
47.2%) (P = 0.002). Significantly more patients in the
tigecycline group reported nausea (26.9% tigecycline ver-
sus 8.5% levofloxacin, P < 0.001), vomiting (16.7% tige-
cycline versus 6.6% levofloxacin, P  = 0.001), and
leukocytosis (6.9% tigecycline versus 0.9% levofloxacin, P
= 0.002), while hypokalaemia was reported significantly
more frequently in the levofloxacin group (0.5% tigecy-
cline versus 3.8% levofloxacin, P = 0.019). The majority of
nausea and vomiting adverse events were reported as mild
to moderate in severity (grades 1 or 2). Severe (grade 3)
nausea and/or vomiting occurred in 3 (1.4%) tigecycline-
treated and 2 (1.0%) levofloxacin-treated patients. In theBMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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tigecycline group, the median time to onset of nausea
and/or vomiting was approximately 1.1 days. The total
duration of nausea or vomiting occurred over a median of
approximately 2.5 days while on tigecycline therapy. Sig-
nificantly more tigecycline-treated subjects (46; 21.3%)
received concomitant medications for nausea/vomiting
compared with the levofloxacin-treated subjects (11;
5.2%) (P ≤ 0.0001). There was no significant difference in
the discontinuation rate from study medication between
the treatment groups for nausea or vomiting.
Drug-related adverse events (as assessed by the investiga-
tor) were reported in 44.4% of tigecycline- and 29.2% of
levofloxacin-treated subjects (P < 0.001; Table 7). Drug-
related digestive system adverse events were the most fre-
quently reported AEs in both treatment groups (32.4% for
tigecycline versus 16.0% for levofloxacin; P < 0.001). Nau-
sea and vomiting occurred more commonly in tigecycline-
treated subjects (25% and 14.4%, respectively) compared
with levofloxacin-treated subjects (7.5% and 4.7%,
respectively; both P < 0.001).
Flow diagram: disposition of patients Figure 1 (see previous page)
Flow diagram: disposition of patients. Patients randomized were included in the intent-to-treat (ITT) population. Those 
who received at least one dose of study drug comprised the modified ITT (mITT) population, and patients in the mITT popula-
tion who had clinical evidence of CAP by meeting the minimal disease criteria made up the clinical modified ITT (c-mITT) pop-
ulation. The microbiologic modified intent-to-treat (m-mITT) population consisted of c-mITT subjects who had 1 or more 
baseline isolates identified. Patients in the c-mITT population were considered to be clinically evaluable (CE) if they satisfied 
inclusion and exclusion criteria, received no more than one dose of a non-once daily non-study antibacterial agent (single agent 
or combination therapy) to treat the current episode of CAP before the first dose of study drug, did not receive other con-
comitant systemic antimicrobial therapy unless a treatment failure, received at least 2 full days of study drug if clinical failure or 
5 full days of study drug if clinical cure, were adherent with therapy (i.e., ≥ 80% but ≤ 120% of medication administered), had an 
assessment of cure or failure at the test-of-cure visit (10-21 days after the last dose of therapy), and the study blind was main-
tained. The microbiologically evaluable (ME) population included CE patients for whom at least one isolate was identified from 
the baseline culture that was susceptible to both test drugs and who had a microbiologic response that could be classified as 
eradication, persistence, or superinfection at the test-of-cure visit.











Male, n (%) 131 (61) 133 (63) 91 (63) 87 (64)
Race, n (%)
White 189 (88) 184 (87) 129 (90) 117 (86)
Black 2 (<1) 4 (2) - 3 (2)
Asian 5 (2) 7 (3) 3 (2) 7 (5)
Other 20 (9) 17 (8) 12 (8) 9 (7)
Mean age ± SD, years (range) 49.9 ± 18.1 (17--92) 49.7 ± 17.4 (18--85) 52.8 ± 16.9 (18--89) 50.4 ± 17.0 (18--85)
Fine Pneumonia Severity Score Index, n (%)
I 32 (15) 41 (19) 18 (13) 23 (17)
II 79 (37) 61 (29) 49 (34) 40 (29)
III 59 (27) 66 (31) 40 (28) 42 (31)
IV 44 (20) 42 (20) 35 (24) 30 (22)
V 2 (<1) 2 (<1) 2 (1) 1 (<1)
Prior antibiotic failure, n (%) 44 (20) 55 (26) 9 (6) 15 (11)
Presence of underlying medical conditions
COPD, n (%) 14 (7) 19 (9) 10 (7) 14 (10)
Diabetes mellitus, n (%) 24 (11) 25 (12) 17 (12) 16 (12)
Alcohol abuse, n (%) 14 (7) 10 (5) 10 (7) 7 (5)
Neoplastic disease, n (%) - 2 (<1) - 2 (2)
Liver disease, n (%) 15 (7) 8 (4) 10 (7) 4 (3)
Congestive heart disease, n (%) 15 (7) 15 (7) 13 (9) 10 (7)
Cerebrovascular disease, n (%) 12 (6) 17 (8) 8 (6) 13 (10)
*There were no statistically significant differences between the treatment groups for demographic or baseline medical characteristics for both the 
mITT and CE populations.BMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
Page 7 of 11
(page number not for citation purposes)
Thirty-nine patients reported a serious adverse event dur-
ing the study period (18 tigecycline, 21 levofloxacin).
Only one serious adverse event (nausea) in a tigecycline-
treated patient was considered related to the study drug;
the event resolved. A total of twelve (12) patients died
during the study: 7 in the tigecycline group and 5 in the
levofloxacin treatment group. All of the deaths were
reported by investigators as either probably not or defi-
nitely not related to the study drug.
There was no statistically significant difference between
tigecycline and levofloxacin in the number of patients in
the mITT population who prematurely discontinued the
study drug (14; 6.5% tigecycline versus 17; 8.0% levo-
floxacin) or withdrew because of any adverse event (4;
1.9% tigecycline versus 5, 2.4% levofloxacin). Mean
change from baseline in laboratory, vital sign, and ECG
parameters was generally small.
Discussion
This multinational, double-blind, randomized, phase 3
clinical trial demonstrated that IV tigecycline (100 mg ini-
tial dose, followed by 50 mg every 12 hours) is as effective
as IV levofloxacin (500 mg once- or twice-daily) for the
treatment of hospitalized adult patients with CAP. For the
280 clinically evaluable patients, clinical cure rates were
88.9% for tigecycline and 85.3% for levofloxacin at the
test-of-cure visit, with tigecycline meeting the statistical
criteria for non-inferiority compared with levofloxacin, a
widely used agent in this setting. These findings were con-
firmed in the co-primary c-mITT population. We also
observed that tigecycline generally achieved good cure
Table 2: Cure Rates at the Test-of-Cure Visit*
Tigecycline Levofloxacin Difference (Tigecycline - Levofloxacin)






CE, Overall 128/144 88.9 (82.6,93.5) 116/136 85.3 (78.2, 90.8) 3.6 (-4.5, 11.8) <0.001 0.4025
Fine <III 60/67 89.6 (79.7, 95.7) 55/63 87.3 (76.5, 94.4) 2.3 (-10.3, 14.8) 0.0026 0.8993
Fine III 34/40 85.0 (70.2, 94.3) 35/42 83.3 (68.6, 93.0) 1.7 (-16.6, 19.9) 0.0388 1.0000
Fine IV 32/35 91.4 (76.9, 98.2) 25/30 83.3 (65.3, 94.4) 8.1 (-11.2, 27.4) 0.0079 0.5463
Fine V 2/2 100.0 (15.8, 100.0) 1/1 100.0 (2.5, 100.0) 0 (-75.0, 75.0) - -
Estimated CURB-65 
0-1
87/97 89.7 (81.9, 94.9) 79/93 84.9 (76.0, 91.5) 4.7 (-5.6, 15.3)
Estimated CURB-65 
2
31/36 86.1 (70.5, 95.3) 30/34 88.2 (72.5, 96.7) -2.1 (-20.3, 16.6)
CURB-65 ≥ 3 10/11 90.9 (58.7, 99.8) 7/9 77.8 (40.0, 97.2) 13.1 (-25.3, 51.7)
c-mITT 170/203 83.7 (77.9, 88.5) 163/200 81.5 (75.4, 86.6) 2.0 (-5.5, 9.6) <0.001 0.6269
*At the test-of-cure visit, each patient's response was categorized as one of the following: Cure---All signs and symptoms of pneumonia present at 
baseline were improved or resolved at test-of-cure with no worsening or appearance of new signs and symptoms of pneumonia and no 
requirement for further antibiotic therapy. Chest radiographs were improved or not worse. Failure---Persistence or worsening in signs and 
symptoms of the acute process with either failure to show improvement in the clinical findings, initial improvement in signs and symptoms followed 
by clinically significant worsening before the test-of-cure assessment, additional antimicrobial therapy required, progression of chest radiograph 
abnormalities, or death after study day 2 because of pneumonia; or Indeterminate---the patient was lost to follow-up, or died within 2 days after the 
first dose of study drug for any reason, or died after 2 days because of noninfectious-related reasons or infection other than pneumonia (as judged 
by the investigator). CE = clinically evaluable population; c-mITT = clinical-modified intent-to-treat population.
Table 3: Cure Rates by Monomicrobial/Polymicrobial Infection at the Test-of-Cure Visit
Tigecycline Levofloxacin Difference (Tigecycline -- Levofloxacin)
n/N % (95% CI) n/N % (95% CI) % (95% CI)
ME
Monomicrobial 53/58 91.4 (81.0, 97.1) 56/64 87.5 (76.8, 94.4) 3.9 (-9.0, 16.3)
Polymicrobial 25/28 89.3 (71.8, 97.7) 20/21 95.2 (76.2, 99.9) -6.0 (-25.1, 16.6)
m-mITT
Monomicrobial 74/84 88.1 (79.2, 94.1) 76/88 86.4 (77.4, 92.8) 1.7 (-9.4, 12.7)
Polymicrobial 28/34 82.4 (65.5, 93.2) 23/25 92.0 (74.0, 99.0) -9.6 (-28.4, 12.4)
ME = microbiologically evaluable population; m-mITT = microbiologic-modified intent-to-treat population.BMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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rates and was very consistent when analyzed by demo-
graphic characteristics and co-morbid conditions, and by
a variety of risk factors, including the Fine Pneumonia
Severity Index [16]. Because bacteremia can be a fatal
complication among patients with CAP, it is also encour-
aging that tigecycline provided an excellent cure rate
(90.9%) in ME patients with S. pneumoniae bacteremia.
Because most of the microbiologic eradication rates by
patient were presumed based on clinical response, little
can be said about this secondary endpoint. ME subjects
with S. pneumoniae isolates, the most common isolate by
far, achieved clinical cures in 92% and 86% of tigecycline-
and levofloxacin-treated subjects, respectively. Although
the number of penicillin-intermediate or -resistant strains
was low, both antimicrobials eradicated 100% of penicil-
lin-intermediate (n = 8) and penicillin-resistant (n = 5)
strains, although 1 of the 3 levofloxacin-treated subjects
with penicillin-resistant S. pneumoniae did not achieve a
clinical cure. High clinical cure/eradication rates were
achieved against M. pneumoniae, the second most com-
monly identified organism, with both treatments; the cure
rates for the ME population were 96% and 92%, respec-
tively. Good cure rates were generally achieved with tige-
cycline against a number of other commonly encountered
respiratory pathogens, including Legionella pneumophila
(although there were small numbers of subjects with this
pathogen), supporting in vitro observations that tigecy-
cline has broad-spectrum activity against isolates fre-
quently encountered in patients with CAP [15,18,19].
The current study also confirmed the in vitro activity of
tigecycline against respiratory isolates, with MIC90s of ≤
1.0 μg/mL against the common gram-positive and gram-
negative respiratory aerobes. Tigecycline has good in vitro
activity against resistant organisms (e.g., penicillin-resist-
ant S. pneumoniae,) [15,18,19]. It is now recognized that
tigecycline binds to bacterial ribosomes in a novel way
that allows it to overcome tetracycline resistance due to
ribosomal protection [20].
Tigecycline and levofloxacin were generally well-tolerated
in the current trial. Tigecycline-treated patients reported
significantly more treatment-emergent adverse events
overall (62.5% versus 47.2%; P  = 0.002), as well as
adverse events considered drug-related by the investigator
(44.4% versus 29.2%; P < 0.001). As has been reported in
other tigecycline studies, gastrointestinal adverse events
were the most frequently reported treatment-emergent
and drug-related adverse events. For treatment-emergent
Table 4: Microbiologic Response for Common Respiratory Pathogens at Test-of-Cure Visit in the ME Population
Tigecycline Levofloxacin
Isolate n/N % (95% CI) n/N % (95% CI)
Streptococcus pneumoniae 46/50 92.0 (80.8, 97.8) 32/36 88.9 (73.9, 96.9)
Penicillin-intermediate S. pneumoniae 3/3 100 (29.2,100) 5/5 100 (47.8, 100)
Penicillin-resistant S. pneumoniae 2/2 100 (15.8, 100) 3/3 100 (29.2, 100)
Haemophilus influenzae 8/11 72.7 (39.0, 94.0) 6/7 85.7 (42.1, 99.6)
Haemophilus parainfluenzae 5/5 100 (47.8, 100) 9/9 100 (66.4, 100)
Klebsiella pneumoniae 4/4 100 (39.8, 100) 7/7 100 (59.0, 100)
Staphylococcus aureus (all non-MRSA) 7/9 77.8 (40.0, 97.2) 6/6 100 (54.1, 100)
Chlamydia pneumoniae 5/5 100 (47.8, 100) 11/11 100 (71.5, 100)
Mycoplasma pneumoniae 24/25 96.0 (79.6, 99.9) 22/24 91.7 (73.0, 99.0)
Legionella pneumophila 3/3 100 (29.2, 100) 5/5 100 (47.8, 100)
MRSA: methicillin-resistant Staphylococcus aureus
Table 5: MIC Range, and MIC50 and MIC90Values of Common Respiratory Pathogens in the ME Population
Tigecycline Levofloxacin
Isolate n MIC Range MIC50 MIC90 n MIC Range MIC50 MIC90
Streptococcus pneumoniae
(penicillin susceptible)
45 0.030, 0.120 0.060 0.060 45 0.250, 2.000 1.000 1.000
Penicillin-intermediate S. pneumoniae 8 0.060, 0.060 NA NA 8 1.000, 1.000 NA NA
Penicillin-resistant S. pneumoniae 5 0.060, 0.060 NA NA 5 1.000, 2.000 NA NA
Haemophilus influenzae 18 0.120, 0.500 0.250 0.500 18 0.120, 0.120 0.120 0.120
Haemophilus parainfluenzae 13 0.250, 0.500 0.500 0.500 13 0.120, 0.120 0.120 0.120
Klebsiella pneumoniae 11 0.250, 2.000 0.500 1.000 11 0.120, 0.500 0.120 0.120
Staphylococcus aureus (all non-MRSA) 15 0.120, 0.250 0.120 0.120 15 0.120, 0.250 0.120 0.250
MRSA: methicillin-resistant Staphylococcus aureusBMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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adverse events, this was the case in both the tigecycline
(38%) and levofloxacin treatment groups (21%; P  <
0.001). While rates of nausea and vomiting were reported
significantly more often among tigecycline patients, most
events occurred early, were of mild to moderate severity,
and resolved within a few days without the need to stop
the drug prematurely. However, concomitant medications
for nausea/vomiting were given four times as often among
tigecycline patients (P ≤ 0.0001). There were no signifi-
cant differences between treatment groups in the fre-
quency of serious adverse events, discontinuations,
including those from adverse events, and deaths. There
were 12 deaths in the study (2.8%); none of the deaths
were considered by the investigators to be related to the
study drugs. The adverse event profile after tigecycline
therapy in this study supports previous safety data from
phase 3 studies [21,22].
Conclusion
In summary, IV tigecycline was found to be generally well-
tolerated and comparable with respect to efficacy to IV lev-
ofloxacin in the treatment of hospitalized adult patients
with CAP. Results of this phase 3 study also demonstrate
that tigecycline achieved good cure rates against the most
frequently encountered respiratory pathogen, S. pneumo-
niae, and against the other common respiratory patho-
gens, including Legionella pneumophila and other atypical
organisms. Treatment of CAP is complicated by rising
rates of antibiotic-resistant bacteria, and there is growing
concern about widespread fluoroquinolone use and rising
rates of fluoroquinolone-resistance among S. pneumoniae.
Based on the results of this study, tigecycline may provide
an alternative option for the treatment of hospitalized
patients with CAP [23-25].
Table 6: Treatment-Emergent Adverse Events that Occurred in ≥ 3% of Patients (mITT Population), Number of Patients (%)
Body System Tigecycline Levofloxacin Total Fisher Exact







Any adverse event 135 62.5 100 47.2 235 54.9 0.002*
Body as a whole 29 13.4 26 12.3 55 12.9 0.774
Headache 10 4.6 4 1.9 14 3.3 0.173
Digestive system 82 38.0 44 20.8 126 29.4 <0.001*
Diarrhoea 16 7.4 17 8.0 33 7.7 0.858
Nausea 58 26.9 18 8.5 76 17.8 <0.001*
Vomiting 36 16.7 14 6.6 50 11.7 0.001*
Haemic and lymphatic system 31 14.4 11 5.2 42 9.8 0.002*
Leukocytosis 15 6.9 2 0.9 17 4.0 0.002*
Thrombocythaemia 11 5.1 4 1.9 15 3.5 0.112
Metabolic and nutritional 20 9.3 26 12.3 46 10.7 0.351
ALT/SGPT increased 4 1.9 9 4.2 13 3.0 0.169
AST/SGOT increased 4 1.9 7 3.3 11 2.6 0.378
Hypokalaemia 1 0.5 8 3.8 9 2.1 0.019*
Abbreviation: ALT/SGPT = alanine aminotransferase (serum glutamic pyruvic transaminase); AST/SGOT = aspartate aminotransferase/serum 
glutamic oxaloacaetic transaminase.
Some subjects had more than 1 treatment-emergent adverse event.
*Significant between-group difference at 0.05 level.
Table 7: Drug-Related Adverse Events that Occurred in ≥ 3% of Patients (mITT Population), Number of Patients (%)
Body System Tigecycline Levofloxacin Total Fisher Exact
Adverse Event (N = 216) 
n (%)





Any adverse event 96 44.4 62 29.2 158 36.9 0.001*
Body as a whole 10 4.6 10 4.7 20 4.7 1.000
Cardiovascular system 9 4.2 5 2.4 14 3.3 0.416
Digestive system 70 32.4 34 16.0 104 24.3 <0.001*
Diarrhoea 15 6.9 14 6.6 29 6.8 1.000
Nausea 54 25.0 16 7.5 70 16.4 <0.001*
Vomiting 31 14.4 10 4.7 41 9.6 <0.001*
Haemic and lymphatic system 7 3.2 4 1.9 11 2.6 0.544
Metabolic and nutritional 15 6.9 16 7.5 31 7.2 0.854
Some subjects had more than 1 drug-related adverse event.
*Significant between-group difference at 0.05 level.BMC Pulmonary Medicine 2009, 9:44 http://www.biomedcentral.com/1471-2466/9/44
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